Business Overview: BeOne Medicines Ltd. (Nasdaq: ONC)

---

Executive Summary

BeOne Medicines Ltd. (formerly BeiGene, Ltd.) is a global, commercial-stage oncology company built around the discovery, development, manufacturing, and commercialization of cancer therapies. The company was founded in 2010 in Beijing and built a dual R&D and commercial footprint spanning the U.S., China, Europe, and Australia. In 2025 the company redomiciled from the Cayman Islands to Switzerland (Basel) and rebranded from BeiGene to BeOne Medicines, changing its Nasdaq ticker from BGNE to ONC (effective January 2, 2025) to reflect its evolution into a diversified, globally-headquartered oncology company rather than a China-centric biotech.

BeOne is anchored by BRUKINSA (zanubrutinib), a next-generation BTK inhibitor that in 2025 became the best-selling BTK inhibitor globally by quarterly revenue, surpassing AstraZeneca's Calquence. The company also markets TEVIMBRA (tislelizumab), an anti-PD-1 checkpoint inhibitor, alongside a broadening portfolio of internally discovered and in-licensed oncology assets.

BeOne matters because it is one of the only biotechs of Chinese origin to have built a genuinely global, fully-integrated commercial and manufacturing operation (R&D in Cambridge/San Mateo/Beijing/Basel, large-molecule manufacturing in Hopewell, NJ, and small- and large-molecule manufacturing in Suzhou and Guangzhou, China) and to translate that into GAAP profitability. Fiscal year 2025 total revenue reached $5.34 billion (+40% YoY), and the company posted its first full year of GAAP net income ($286.9 million), a milestone that marks its transition from a cash-burning clinical-stage biotech to a self-funding, large-cap global pharma competitor.

---

1. Core Business Model & How They Work

BeOne operates the standard biopharmaceutical value-creation cycle, but distinguished by an unusually integrated, vertically-built global infrastructure (its own manufacturing, its own ex-China and China commercial salesforces, and its own global clinical operations) rather than heavy reliance on partners or CROs:

[ Internal Discovery (Beijing/Cambridge/San Mateo) ] ➡️ [ Global Clinical Trials (US/EU/China/APAC) ] ➡️
[ Regulatory Filings (FDA, NMPA, EMA) ] ➡️ [ Owned Manufacturing (Hopewell NJ; Suzhou & Guangzhou, China) ] ➡️
[ Direct Commercialization (US, Europe, China, APAC salesforces) ] ➡️ [ Patent-Protected Revenue ] ➡️ [ Reinvest in Pipeline / BD ]

Key Operational Drivers

1. Internally-Discovered Blockbusters: Unlike many mid-cap biotechs that rely primarily on licensed-in assets, BeOne's two largest products — BRUKINSA and TEVIMBRA — were discovered in-house, giving it full economics and global commercialization rights rather than splitting royalties with a partner.
2. Owned Global Manufacturing: BeOne operates large-molecule biologics capacity in Hopewell, New Jersey (~8,000 liters, where TEVIMBRA's process is qualified) and in Guangzhou, China (~64,000 liters, expanding toward ~65,000+), plus small-molecule manufacturing in Suzhou, China (~600 million tablets/capsules annually). This reduces reliance on third-party CMOs for its highest-volume products.
3. China-to-Global Playbook: BeOne's model has historically been to in-license Western/global assets for the China market (e.g., Amgen's XGEVA, BLINCYTO, KYPROLIS; Novartis oncology brands) to fund and scale a China commercial organization, while pushing its own internally-discovered molecules (BRUKINSA, TEVIMBRA) through global registration outside China. That flywheel is now largely complete, with BRUKINSA generating more revenue in the U.S. ($2.8B in 2025) than in China.
4. R&D Reinvestment at Scale: BeOne spent $2.15 billion on R&D in 2025 (up 10% YoY) across a deep pipeline (BCL2, BTK degrader, CDK4, multiple ADCs and bispecifics, 70+ preclinical programs), funded increasingly from operating cash flow rather than capital raises.

---

2. Business Segments

BeOne does not break out multiple reportable operating segments in its financial disclosures — it operates and reports as a single oncology biopharmaceutical business, organized internally by geography (U.S., China/APAC, Europe) and product line rather than as distinct reporting segments. This section is therefore omitted in favor of the product- and geography-level detail below.

---

3. Product Portfolio

---

4. Competitive Landscape

BeOne competes against large-cap global pharma and a growing field of China-based oncology biotechs, with competitive intensity varying sharply by drug class.

            ONCOLOGY COMPETITIVE POSITIONING
   High  ┌───────────────────────────────────────────────────┐
         │                                  [Merck-KEYTRUDA]  │
   G     │                      [BMS-OPDIVO]                  │
   L     │         [BEONE]                                    │
   O     │    (BTK leader;         [AstraZeneca-IMFINZI/      │
   B     │   growing IO/ADC)         CALQUENCE]                │
   A     │                                                     │
   L     │  [Innocare]      [Eli Lilly-JAYPIRCA]               │
   S     │  [Ascentage]                                        │
   C     │  [Junshi/Henlius]                                   │
   A     │                                                     │
   L  Low└───────────────────────────────────────────────────┘
         Low          PORTFOLIO BREADTH (single-drug → multi-franchise)       High

Competitors by Drug Class

BTK Inhibitors (BRUKINSA)

• Key Competitors: AbbVie/Janssen (Imbruvica), AstraZeneca (Calquence), Eli Lilly (Jaypirca), Innocare (Orelabrutinib, China/Singapore).
• Dynamics: BRUKINSA overtook Calquence as the top-selling BTK inhibitor by quarterly revenue in late 2024 and widened that lead through 2025 ($950M vs. Calquence's $872M in Q2 2025) on superior head-to-head cardiac-safety and efficacy data versus Imbruvica. AstraZeneca is countering with fixed-duration Calquence combinations now approved in the EU and under FDA review; Eli Lilly's non-covalent Jaypirca is pushing into earlier treatment lines, which BeOne is answering with its own BTK degrader, BGB-16673, and a sonrotoclax/BRUKINSA fixed-duration combination (Celestial-301).

PD-1/PD-L1 Immuno-Oncology (TEVIMBRA)

• Key Competitors: Merck (Keytruda), Bristol Myers Squibb (Opdivo), AstraZeneca (Imfinzi), Roche (Tecentriq), Merck KGaA (Bavencio), Regeneron/Sanofi (Libtayo), GSK (Jemperli), plus China-based Junshi (Loqtorzi) and Henlius (Hansizhuang).
• Dynamics: This is the single most crowded oncology category globally, with 20+ competing PD-1/PD-L1 and IO-bispecific products in China alone. TEVIMBRA is a clear share-taker rather than the category leader — it competes largely on price and on differentiated indications (e.g., first-line gastroesophageal cancer) rather than Keytruda's overwhelming breadth (30+ approved indications).

BCL2 Inhibitors (Sonrotoclax)

• Key Competitors: AbbVie/Roche (Venclexta, the incumbent), Ascentage Pharma (lisaftoclax, global Phase 3), Innocare (mesutoclax).
• Dynamics: Sonrotoclax is the challenger, but BeOne is betting its combination strategy with BRUKINSA (fixed-duration dosing) differentiates it from Venclexta's combination regimens.

---

5. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• BTK Category Leadership with Clinical Differentiation: BRUKINSA's superior cardiac-safety profile versus Imbruvica and now-larger revenue base than Calquence give it real prescriber-preference momentum, not just price-based share.
• Vertically Integrated Global Manufacturing: Owned biologics and small-molecule plants in New Jersey and China reduce supply-chain and margin risk that pure licensing-model biotechs don't have, and support the ~87% GAAP gross margin on product sales.
• Dual-Market Commercial Infrastructure: A rare combination of a mature U.S./EU commercial organization and a large, established China salesforce (built partly by commercializing in-licensed Amgen and Novartis products), giving BeOne a distribution advantage over most single-geography biotechs.
• Deep, Diversified Pipeline: 70+ preclinical programs plus multiple pivotal-stage assets (sonrotoclax, BGB-16673, several ADCs/bispecifics) reduce single-asset concentration risk relative to where the company stood five years ago.

Strategic Risks & Vulnerabilities

BRUKINSA Revenue Concentration
--------------------------------------------------------------
2025                              2026+
[~73% of total revenue from one drug] ➡️ [Intensifying BTK-class competition]

1. Single-Product Revenue Concentration: BRUKINSA represented roughly 73% of 2025 total revenue; any erosion from Calquence's fixed-duration combinations, Jaypirca's push into earlier lines, or new non-covalent/degrader entrants (including from Nurix Therapeutics) would disproportionately hit overall results.
2. Intensely Crowded PD-1 Field: TEVIMBRA faces the most competitively saturated class in oncology, including low-cost China-originated PD-1 products, limiting pricing power and ceiling on share gains.
3. China Regulatory and Macro Exposure: A meaningful share of manufacturing (Suzhou, Guangzhou) and revenue still sits in China, exposing BeOne to NMPA pricing/reimbursement (National Reimbursement Drug List) pressure, geopolitical friction, and potential U.S.–China biotech policy risk (e.g., scrutiny of China-linked biopharma under evolving U.S. legislation).
4. Recency of Profitability: 2025 was BeOne's first full year of GAAP profitability; GAAP operating margin (~8%) remains thin relative to R&D intensity (R&D was ~40% of revenue), so execution risk on pipeline conversion (sonrotoclax, BGB-16673, ADCs) is high — a stumble in any pivotal trial could push the company back to losses.
5. Execution Risk Post-Redomiciliation: The 2025 Cayman-to-Switzerland redomiciliation and BeiGene-to-BeOne rebrand, while strategically framed around global maturity and tax/trade treaty access, add corporate complexity and integration risk during a period of rapid commercial scaling.

---

6. Financial Overview

---

7. Summary Conclusion

BeOne Medicines has completed an unusual transformation: a China-founded, once cash-burning clinical-stage biotech that has become a genuinely global, vertically-integrated, GAAP-profitable oncology company with $5.3 billion in 2025 revenue. Its moat rests on BRUKINSA's clinical differentiation and category leadership in BTK inhibition, reinforced by owned manufacturing and a rare dual U.S.–China commercial footprint that few peers can replicate.

The central tension going forward is that BeOne's profitability and growth still rest overwhelmingly on a single drug class under mounting competitive pressure from AstraZeneca, Eli Lilly, and emerging BTK degraders, while its second act — sonrotoclax, BGB-16673, and a widening ADC/bispecific pipeline — must convert from promising pivotal data into durable, diversified revenue before BTK-class competition erodes BRUKINSA's lead. How well BeOne executes that pipeline conversion over the next two to three years, while managing its still-meaningful China exposure, will determine whether its 2025 profitability inflection is the start of a durable large-cap pharma trajectory or a high-water mark.